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THE FUTURE OF DIRECT-TO-CONSUMER GENETIC TESTING:
REGULATION AND INNOVATION
Chelsea Weiermiller*
Direct-to-consumer (“DTC”) genetic testing companies face
regulation from numerous parties. The Food and Drug
Administration has taken the lead role in the regulation of this
industry. The Federal Trade Commission must make sure that
consumers are not misled by unscrupulous marketing and false
advertising. The Centers for Medicare and Medicaid Services
under the Clinical Laboratory Improvement Amendments should
ensure that genetic tests are analytically and clinically valid. State
laws and federal statutes like the Genetic Information
Discrimination Act address consumer privacy concerns. The recent
Molecular Pathology v. Myriad Genetics, Inc. Supreme Court
decision will shape the direction of DTC genetic testing patents.
Case law is also influencing DTC genetic consumer protection.
These various regulatory mechanisms must strike a balance
between protecting DTC genetic test consumers without stifling
important innovations in this industry.
I. INTRODUCTION
Imagine the possibility of medical treatments tailored to your
DNA. Although personalized medicine might be a long way off,1 a
simple medical test taken in the privacy of your home could tell

*
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and Ben Szany.
1
See Press Release, Am. Chem. Soc’y, Personalized Medicine Has Finally
Arrived – or Has It? (Feb. 26, 2014) available at http://www.acs.org/content/
acs/en/pressroom/presspacs/2014/acs-presspac-february-26-2014/personalizedmedicine-has-finally-arrived-or-has-it.html.
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you the likelihood of contracting a specific disease. 2 Genetic
testing can identify changes in your gene expression3 to determine
your risk of developing a genetic disorder, or serve to confirm the
existence of a genetic condition.4 Some companies market genetic
tests directly to consumers. 5 These companies have provided
consumers with access to genetic information without involving
doctors or insurance companies in the process.6
Direct-to-Consumers (“DTC”) genetic tests have generated a
great deal of controversy. 7 Since the Human Genome Project
concluded in April 2003, 8 DNA sequencing has become
exponentially faster and much more affordable.9 In the late 2000’s,
several companies emerged to take advantage of the burgeoning
consumer demand for genetic information via the Internet.10 Rather
2

See Direct to Consumer Genetic Tests, U.S. FTC (Jan. 2014), http://www.
consumer.ftc.gov/articles/0166-direct-consumer-genetic-tests.
3
The epigenome consists of chemical compounds from things like food,
medicine, or pesticides that mark and change the genome over time. Epigenetics
might help explain differences between identical twins. Although twins might
have almost the exact same genome and DNA, one identical twin could develop
arthritis, for example, due to environmental changes over the course of his or her
lifetime. Epigenomics, NAT’L HUMAN GENOME RESEARCH INST. (May 7, 2012),
http://www.genome.gov/27532724.
4
What is Genetic Testing?, GENETICS HOME REFERENCE (Nov. 4, 2014),
http://ghr.nlm.nih.gov/handbook/testing/genetictesting.
5
See Pascal Su, Direct-to-Consumer Genetic Testing: A Comprehensive View,
86 YALE J. BIOL. MED. 359, 359 (2013).
6
What is Direct-to-Consumer Genetic Testing?, GENETICS HOME REFERENCE
(Nov. 4, 2014), http://ghr.nlm.nih.gov/handbook/testing/directtoconsumer.
7
James P. Evans & Robert C. Green, Commentary, Direct to Consumer
Genetic Testing: Avoiding a Culture War, 11 GENETICS IN MED. 568, 568 (2009).
8
All about the Human Genome Project (HGP), NAT’L HUMAN GENOME
RESEARCH INST., http://www.genome.gov/10001772 (last updated Mar. 18, 2014).
9
The Human Genome Project cost $1 billion and 8 years to complete. As of
2013, Eric D. Green, the director of the National Human Genome Research
Institute, estimated it would take several days and as little as $4000–$5000 to
sequence an entire human genome. Gina Kolata, Human Genome, Then and
Now, N.Y. TIMES (Apr. 15, 2013), http://www.nytimes.com/2013/04/16/science/
the-human-genome-project-then-and-now.html?_r=0.
10
In 2011, the Genetics and Public Policy Center released an updated list of
twenty Direct-to-Consumer Genetic Testing companies, including: 23andMe,
Advanced Healthcare, Inc., deCODE Genetics, Holistic Health, and Map My
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than sequencing the entire human genome as the Human Genome
Project did, these companies examined single nucleotide
polymorphisms 11 (“SNPs”)—DNA sequences in the genome that
usually differ between individuals.12 SNP tests analyze a person’s
ancestry and health, as well as a number of other traits.13 Generally,
DTC genetic testing companies advertise and operate online. 14
Although the specifics between DTC genetic testing companies
may vary, generally a consumer purchases the product online, and
then receives a test kit in the mail.15 Next, the consumer performs a
cheek swab or obtains a saliva sample.16 The consumer then sends
the test kit back to the genetic testing company where it is analyzed
by a lab.17 The consumer receives the results either online or by
mail.18
In 2010, about 30 companies offered more than 400 different
DTC genetic tests.19 However, due to increased state and federal

Gene, among others. See GENETICS & PUB. POLICY CTR., GPPC RELEASES
UPDATED LIST OF DTC GENETIC TESTING COMPANIES (2012), available at
http://www.dnapolicy.org/resources/DTCTableAug2011Alphabydisease.pdf.
11
SNPs occur throughout a person’s DNA, sometimes acting as genetic
markers. Although most SNPs do not have any effect on human health and
development, researchers have found that some SNPs can predict drug responses
and track inheritance of disease genes. There are about 10 million SNPs in the
human genome, occurring once every 300 nucleotides. What are Single
Nucleotide Polymorphisms (SNPs)?, GENETICS HOME REFERENCE (Nov. 4,
2014), http://ghr.nlm.nih.gov/handbook/genomicresearch/snp.
12
Direct-to-Consumer Genetic Testing, PERS. GENETICS EDUC. PROJECT,
http://www.pged.org/direct-to-consumer-genetic-testing (last visited Oct. 20,
2014).
13
DTC genetic testing companies report traits ranging from “a person’s ability
to taste bitter flavors or the photic sneeze reflex (uncontrollable sneezing when
exposed to bright light) to risk for developing heart disease or diabetes.” Id.
14
Kayte Spector-Bagdady & Elizabeth Pike, Consuming Genomics: Regulating
Direct-to-Consumer Genetic and Genomic Information, 92 NEB. L. REV. 677,
689 (2014).
15
Id.
16
Id.
17
Id.
18
Id.
19
Arthur L. Beaudet & Gail Javitt, Which Way For Genetic-Test Regulation?,
466 NATURE 816, 817 (2010).
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regulation, many DTC genetic testing companies have
discontinued selling their health-related products.20
On November 22, 2013, 23andMe Inc.—the last major DTC
genetic testing company offering health-related genetic test
services—received a formal warning letter from the Food and
Drug Administration (“FDA”) forcing the company to cease
marketing its health-related Personal Genome Service.21 The FDA
warned that 23andMe was selling its Personal Genome Service
“without marketing clearance or approval in violation of the
Federal Food Drug and Cosmetic Act.” 22 The FDA seemed
especially frustrated that 23andMe stopped communicating with
the agency in May 2013 while initiating new marketing strategies
including televised commercials for the Personal Genome
Service.23
Despite the agency’s harsh rebuke, as of June 20, 2014,
23andMe is again in talks with the FDA to gain preliminary
approval24 for its test for Bloom syndrome, a rare genetic disorder
20
Spector-Bagdady & Pike, supra note 14, at 680. The FDA started to enforce
against DTC genetic testing companies in May 2010, after Pathway Genomics
announced plans to start selling its home use saliva kit at more than 6000
Walgreens Stores, making the product the company had been selling online for
years much more accessible to consumers. The FDA was concerned about the
health-related claims the company was making, and announced its concern that
the company was marketing an unapproved medical device. The FDA sent out
five additional letters to genetic testing companies (23andMe, Knome,
Navigenics, deCODE Genetics and Illumina) in June 2010, and fourteen more in
July 2010 to companies that appeared to be marketing FDA defined medical
devices without clearance. Id. at 706–08.
21
Letter from Alberto Gutierrez, Dir. Office of In Vitro Diagnostics and
Radiological Health, Ctr. For Devices and Radiological Health, Food and Drug
Admin., U.S. Dep’t. of Health and Human Servs., to Anne Wojcicki, C.E.O., 23
and Me, Inc. (Nov. 22, 2013), http://www.fda.gov/iceci/enforcementactions/
warningletters/2013/ucm376296.htm [hereinafter Warning Letter to Wojcicki].
22
Id.
23
See id.
24
According to the FDA’s website, a 510(k) application is required for premarket
approval for a new medical device to demonstrate that the device is at least as
safe and effective as a legally marketed device. 510(k) Clearances, U.S. FOOD AND
DRUG ADMIN., http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/
DeviceApprovalsandClearances/510kClearances/ (last updated June 6, 2014).
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involving a single mutation to one gene. 25 If 23andMe’s 510(k)
application for Bloom syndrome is successful, the submission will
help establish parameters for future genetic test submissions, and
will serve to assure DTC genetic testing consumers that the tests
are valid.26
This Recent Development argues that the Federal Trade
Commission (“FTC”), FDA, Centers for Medicare and Medicaid
Services (“CMS”), and other federal regulatory agencies should
enforce regulations against DTC genetic testing companies making
dubious scientific claims, but exercise enforcement discretion
against companies that demonstrate robust scientific findings in
order to make these DTC genetic tests safe for consumers without
stifling important innovations. Part II examines the current
regulatory status of the DTC genetic testing industry and analyzes
the role of the various stakeholders in the ongoing efforts to
regulate this industry. Part III considers the implications of the
latest developments in the DTC genetic testing industry in a case
study of one DTC genetic testing company, Interleukin Genetics.
This Recent Development argues for more coordinated regulation
of the DTC genetic testing industry because concerns of consumer
autonomy and industry innovation outweigh the potential harm of
most of these tests.
II. THE CURRENT REGULATORY STATUS: INSTITUTIONAL
PERSPECTIVES
Various institutions regulate the DTC genetic testing
companies, and several federal agencies will likely play oversight
roles. These agencies include the FDA, CMS under the Clinical
Laboratory Improvement Amendments (“CLIA”), the FTC, and
the Equal Opportunity Employment Commission (“EEOC”) under
the Genetic Information Nondiscrimination Act (“GINA”). States
also play an important part in the regulation of this industry.

25

Update on the Regulatory Review Process with the FDA, 23ANDME BLOG
(June 20, 2014), http://blog.23andme.com/news/update-on-the-regulatory-reviewprocess-with-the-fda/.
26
See id.
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Finally, this part considers important case law affecting the DTC
industry.
A. Food and Drug Administration: Regulation of the DTC Industry
The FDA leads the regulation of the DTC genetic testing
industry.27 The FDA derives its authority to regulate the sale and
distribution of medical devices from the Food Drug and Cosmetic
Act.28 Genetic tests, as a category of in vitro diagnostic (“IVD”)
devices, 29 generally fall under the definition of medical device 30
and are therefore subject to regulation by the FDA.31 IVD refers to
27
See Direct to Consumer Genetic Testing and the Consequences to the
Public: Hearing Before the Subcomm. on Oversight and Investigations of the H.
Comm. on Energy and Commerce, 111th Cong. (2010) (statement of Jeffrey
Shuren, M.D., Dir. For Devices and Radiological Health, Food & Drug Admin.,
Dep’t. of Health and Human Serv’s.), available at http://www.fda.gov/
NewsEvents/Testimony/ucm219925.htm [hereinafter Shuren—Statement].
28
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301–399f (2006).
29
In Vitro Diagnostic Products for Human Use, 21 C.F.R. § 809.3(a) (2013)
(“[I]n vitro diagnostic products are those reagents, instruments, and systems
intended for use in the diagnosis of disease or other conditions, including a
determination of the state of health, in order to cure, mitigate, treat, or prevent
disease or its sequelae. Such products are intended for use in the collection,
preparation, and examination of specimens taken from the human body. These
products are devices as defined in section 201(h) of the Federal Food, Drug, and
Cosmetic Act (the act), and may also be biological products subject to section
351 of the Public Health Service Act.”).
30
Medical device is defined as:
an instrument, apparatus, implement, machine, contrivance, implant, in
vitro reagent, or other similar or related article, including any component
part, or accessory that is intended for use in the diagnosis of disease or other
conditions, or in the cure, mitigation, treatment, or prevention of disease, in
man or other animals, or is intended to affect the structure or function of the
body of man or other animals.
21 U.S.C § 321(h) (2013).
31
AMANDA K. SARATA & JUDITH A. JOHNSON, CONG. RESEARCH SERV.,
R43438, REGULATION OF CLINICAL TESTS: IN VITRO DIAGNOSTIC (IVD)
DEVICES, LAB. DEV.TESTS (LDTS), AND GENETIC TESTS 1 (2014). But see
Michael Eisen, FDA vs. 23andMe: How Do We Want Genetic Testing to be
Regulated?, IT IS NOT JUNK (Nov. 26, 2013), http://www.michaeleisen.org/
blog/?p=1480 (arguing that the FDA’s definition of a medical device is too
broad to be useful in the case of DTC genetic testing as genetic tests “are closer
to a family history than an accurate diagnostic”).
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a method of performing a diagnostic test outside of the living body
in an artificial environment, usually in a laboratory.32 IVDs differ
from other medical devices because a false positive or false
negative result could potentially harm a patient.33
Between 200734 and 2010, the FDA did not take a substantial
role in regulating DTC genetic testing companies.35 However, by
2010, the FDA stated that it had reconsidered its position regarding
the non-enforcement of these tests because the tests put the patients
at risk for incorrect diagnosis and treatment.36 On July 22, 2010,
Jeffrey Shuren, the Director for Devices and Radiological Health
for the FDA, testified before the U.S. House of Representatives,
explaining that the DTC companies had recently begun “aggressively
market[ing]” to consumers.37 The FDA was particularly concerned
that one company, Pathway Genomics, was planning to sell its
DTC genetic testing product on 6,000 Walgreen’s store shelves,
making their product much more accessible to the average
consumer. 38 Additionally, Shuren pointed out that 23andMe’s
product was accessible to consumers on Amazon.com. 39 Shuren
commented that although many genetic tests were approved after
2003, none of the DTC genetic tests currently on the market had
undergone FDA premarket approval to “ensure that the test results
being provided to patients are accurate, reliable, and clinically
meaningful.” 40 FDA decided to strictly regulate DTC genetic
32
In vitro diagnostic comes from the Latin “within the glass.” IVDs vary
widely—from pregnancy tests to cervical cancer screening tests. IVDs contrast
with other medical technologies because these tests never directly interact with
the human body, but rather derive their use value from the health information
they can provide to a patient. About In Vitro Diagnostics, EUROPEAN
DIAGNOSTIC MFRS. ASS’N, http://www.edma-ivd.be/index.php?page=About-InVitro-Diagnostics (last visited November 1, 2014).
33
See SARATA & JOHNSON, supra note 31, at 1.
34
The first DTC companies 23andMe and deCODEme launched in 2007.
Spector-Bagdady & Pike, supra note 14, at 688.
35
See SARATA & JOHNSON, supra note 31, at 1.
36
Spector-Bagdady & Pike, supra note 14, at 703–04.
37
Shuren—Statement, supra note 27.
38
Id.
39
Id.
40
Id.
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testing companies because these companies were assessing
high-risk diseases, and many of these test manufacturers were
corporations rather than hospitals or public laboratories that the
FDA originally wanted to exempt from regulation.41
Laboratory Developed Tests42 (“LDTs”) are a specific type of
IVD that are designed for clinical use and are manufactured in a
single laboratory.43 Some DTC genetic testing companies conducting
their own analysis and using their own genetic data offer LDTs.44
Traditionally, the FDA exercised discretion not to enforce against
LDTs because these types of tests were relatively simple.45 However,
in recent years, the FDA has noted that these types of tests have
become increasingly complex and “almost indistinguishable” from
other IVDs.46 On July 31, 2014, in a major shift, the FDA issued
new regulatory draft guidance for LDTs “based on risk to patients
rather than whether they were made by a conventional manufacturer
or a single laboratory.” 47 The regulatory guidance imposes the
strictest guidelines for the highest risk LDTs, and recommends
enforcement discretion for lower risk LDTs and LDTs for rare
diseases, among others.48 The FDA is currently seeking feedback
to determine what constitutes a rare disease, and whether the
enforcement discretion should be limited to tests that are designed,
manufactured, and used within a single laboratory.49
The FDA’s planned discretion not to enforce for rare diseases
might have influenced 23andMe’s decision to submit their 510(k)
41

Spector-Bagdady & Pike, supra note 14, at 702.
Laboratory Developed Tests, U.S. FOOD AND DRUG ADMIN., http://www.
fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/uc
m407296.htm (last updated Oct. 3, 2014).
43
“Single laboratory” refers to a facility with a single CLIA certificate as
described in 42 C.F.R. § 493.43(a)–(b).
44
Spector-Bagdady & Pike, supra note 14, at 703.
45
U.S. FOOD AND DRUG ADMIN., supra note 42.
46
Alexander Gaffney, In Major Shift, the FDA to Regulate Lab-Developed
Tests as Normal Devices, REGULATORY AFFAIRS PROF’LS SOC’Y (Aug. 1 2014),
http://www.raps.org/Regulatory-Focus/News/2014/08/01/19934/In-Major-ShiftFDA-to-Regulate-Lab-Developed-Tests-as-Normal-Devices/.
47
U.S. FOOD AND DRUG ADMIN., supra note 42.
48
Id.
49
Id.
42
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application for Bloom syndrome. 50 Although some have heralded
this submission as the first step in getting hundreds of its tests
approved,51 many of 23andMe’s tests are for much more complex
diseases, which might not necessarily fit the FDA’s definition of a
“rare disease” subject to planned LDT enforcement discretion. 52
Anne Wojcicki, CEO of 23andMe, has commented that their tests
are difficult to regulate on a case-by-case basis because the
company does not just offer “a single type of test.”53
While the new regulatory guidance will be phased in over the
next decade or so, politicians, doctors’ groups, and industry leaders
have already reacted negatively to these proposed regulations. 54
For example, the American Medical Association, a powerful
lobbying group for doctors, 55 and the Association for Molecular
Pathology, an association representing molecular testing
companies, 56 have expressed concern about the new framework.

“Bloom syndrome is a very rare disorder in most populations, and its
overall frequency is unknown. The disorder is more common in people of Central
and Eastern European (Ashkenazi) Jewish background, among whom about 1 in
50,000 are affected. Approximately one-third of people with Bloom syndrome
are of Ashkenazi Jewish descent.” Bloom Syndrome, GENETIC HOME REFERENCE,
http://ghr.nlm.nih.gov/condition/bloom-syndrome (last updated Nov. 2010).
51
Robert Hof, Seven Months After FDA Slapdown, 23andMe Returns with
New Health Report Submission, FORBES (June 20, 2014, 12:04 PM), http://
www.forbes.com/sites/roberthof/2014/06/20/seven-months-after-fda-slapdown23andme-returns-with-new-health-report-submission/.
52
For example, nearly 5 million people live with Alzheimer’s disease. Alzheimer’s
Facts and Figures, ALZHEIMER’S ASS’N, http://www.alz.org/alzheimers_disease_
facts_and_figures.asp (last visited Oct. 21, 2014).
53
Robert Hof, ‘We Are Going For Change’: A Conversation with 23andMe
CEO Anne Wojcicki, FORBES (Aug. 15, 2014, 10:50 AM), http://www.forbes.com/
sites/roberthof/2014/08/15/we-are-going-for-change-a-conversation-with-23andmeceo-anne-wojcicki/.
54
Gaffney, supra note 46.
55
Barbara L. McAneny, MD, Chair of the Board, Am. Med. Assoc., AMA
Statement on FDA Proposal Regarding Diagnostic Testing, AM. MED. ASS’N
(Aug. 1, 2014), http://www.ama-assn.org/ama/pub/news/news/2014/2014-08-01fda-proposal-diagnostic-testing.page.
56
The Association for Molecular Pathology Voices Concern with U.S. FDA
Anticipated Details of Laboratory Developed Test Draft Guidance, ASS’N FOR
MOLECULAR PATHOLOGY, http://www.businesswire.com/news/home/20140731006689/
50
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However, AdvaMed, the medical device’s largest trade association,
expressed support for the new regulation, indicating that the
guidance would create parity between currently regulated devices
and unregulated LDTs.57 The new guidance could ultimately affect
up to 11,000 of these DTC genetic tests in up to 2,000 different
laboratories.58
B. Centers for Medicare and Medicaid Services and the Clinical
Laboratory Improvement Act: More Stringent Requirements
Necessary
CMS is another important player in the regulation of the DTC
genetic testing industry. CMS regulates the DTC genetic testing
industry under the Clinical Laboratory Improvement Amendments
Act of 1988 (“CLIA”) 59 Under CLIA, CMS sets standards for
laboratories that provide information about health-related
conditions. 60 However, there are no special requirements for
laboratories performing genetic tests under CLIA.61
Clinical genetic tests are typically evaluated using the ACCE
framework, which includes testing for “analytical validity, clinical
validity, clinical utility, and ethical, social and legal
implications.” 62 Although CLIA assures that genetic tests are
en/Association-Molecular-Pathology-Voices-Concern-U.S.-FDA (last updated July
31, 2014 8:37 PM).
57
AdvaMedDx Commends FDA's Issuance of LDT Draft Framework, ADV.
MED. TECH. ASS’N (July 31, 2014), http://advamed.org/news/117/advameddxcommends-fdas-issuance-of-ldt-draft-framework.
58
Matthew Harper, FDA To Regulate Thousands Of Cancer, Genetic, And
Other Diagnostics, FORBES, http://www.forbes.com/sites/matthewherper/2014/07/31/
fda-to-regulate-thousands-of-cancer-genetic-and-other-diagnostics/ (last updated
July 31, 2014, 1:03 PM).
59
42 C.F.R. § 493.1253 (2003).
60
Kathryn Schleckser, Physician Participation in Direct-to-Consumer Genetic
Testing: Pragmatism or Paternalism?, 26 HARV. J.L. & TECH. 695, 707 (2013).
61
See Genetic Testing: Understanding Your Genes and What They Mean for
Your Health, GENETIC ALLIANCE, http://www.geneticalliance.org/advocacy/
policyissues/genetictesting (last visited Oct. 20, 2014).
62
The ACCE takes its name from the four main criteria for evaluating a
genetic test. ACCE Model Process for Evaluating Genetic Tests, CTRS. FOR DISEASE
CONTROL AND PREVENTION, http://www.cdc.gov/genomics/gtesting/ACCE/ (last
updated Jan. 3, 2010).
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analytically valid (“how well a test recognizes a genetic variant”),
CLIA does not ensure clinical validity (“the association of the
variant with a disease or medical condition”) or clinical utility
(“whether the information of the disease or medical condition can
be of clinical use to a consumer”) of the genetic medical
information.63 Therefore, it is possible that a test could satisfy the
highest analytical standard, but still be inaccurate if there is not a
strong relationship between the genetic variant and the clinical
manifestation of disease.64
In addition, while it is widely recognized that genetic testing is
very complex, there are no proficiency standards for a genetic
testing subspecialty. 65 Because specific proficiency testing for
these genetic tests is not mandated under CLIA, laboratories
determine their own competencies.66
Even if the FDA restricts access to DTC genetic tests, CMS
needs to assure the quality of these tests.67 The government must
correct the systemic gaps in oversight that make consumers
vulnerable to inaccurate results. 68 For example, the Government
Accountability Office (“GAO”) has criticized CMS’s oversight of
CLIA laboratories, finding in 2006 that “CMS failed to sanction
labs with ‘serious, condition-level deficiencies on consecutive
surveys.’”69 CLIA theoretically requires laboratories to ensure the
validity of all tests performed, but as previous GAO reports have

63

Spector-Bagdady & Pike, supra note 14, at 719.
Id. at 721.
65
Id.
66
Gail H. Javitt & Kathy Hudson, Federal Neglect: Regulation of Genetic
Testing, ISSUES IN SCI. & TECH. (Nov. 27, 2013), http://issues.org/22-3/javitt/.
67
See id.
68
Id.
69
Jessica Elizabeth Palmer, Genetic Gatekeepers: Regulating Direct-to-Consumer
Genomic Services in an Era of Participatory Medicine, 67 FOOD & DRUG L.J.
475, 503 (2012) (citing US GOV’T ACCOUNTABILITY OFFICE, GAO-06-416,
CLINICAL LAB QUALITY: CMS AND SURVEY ORGANIZATION OVERSIGHT
SHOULD BE STRENGTHENED, 8 (2006)) (“CMS’s oversight of clinical lab quality
is inadequate to ensure that labs are meeting CLIA requirements.”).
64
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found,70 CMS could do much more to “ensure that their test results
are accurate, reliable, timely, and confidential and do not present
the risk of harm to patients.”71 CMS should do more to make sure
that consumers are getting analytically valid and clinically valid
test results.
C. Federal Trade Commission and the Prevention of Misleading
DTC Genetic Test Marketing
The FTC has broad investigative and enforcement authority to
protect consumers from unfair and deceptive trade practices under
the Federal Trade Commission Act. 72 In 2014, the FTC started
regulating DTC genetic testing companies for the first time,
indicating that the agency plans to play a bigger role in protecting
consumers of DTC genetic tests. 73 For example, the FTC filed
charges against Genelink, Inc in January and L’Oréal USA Inc. in
June for offering purported personalized genetics testing services.74
Genelink and its subsidiary foru™ made claims that its
nutritional products could help compensate for “disadvantaged”
genes. 75 The FTC charged that Genelink and foru™ engaged in
unfair and deceptive trade practices, and made misleading
advertisements in violation of sections 5(a) and 12 of the FTC
Act.76 The FTC wanted to prevent these companies from making

US GOV’T ACCOUNTABILITY OFFICE, GAO-06-416, CLINICAL LAB QUALITY:
CMS AND SURVEY ORGANIZATION OVERSIGHT SHOULD BE STRENGTHENED, 8
(2006), available at http://www.gao.gov/assets/260/250504.pdf.
71
42 C.F.R. § 493.1253(b)(2)(vii) (2013).
72
See 15 U.S.C. § 45(a)(1) (2013).
73
Jennifer K. Wagner, FTC Takes Action to Protect Consumers from False Genetic
Advertising Claims, GENOMICS LAW REPORT, http://www.genomicslawreport.com/
index.php/2014/07/03/ftc-takes-action-to-protect-consumers-from-false-geneticadvertising-claims/#more-13323 (last updated July 3, 2014).
74
Id.
75
Complaint at 1, In re GeneLink, Inc. & Foru Int’l Corp., No. 112-3095
(F.T.C. Jan. 7, 2014).
76
Id. On May 8, 2014, the Commission voted 3-1 to approve the final orders
against the companies. Wagner, supra note 73.
70
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health-related genetic claims “unless the claim is true and
supported by at least two adequate and well-controlled studies.”77
The Council for Responsible Nutrition raised concerns in
public comment that requiring two studies would become a
“de-facto standard,” and that this type of testing by respondents
would create an “undue burden.” 78 Furthermore, the Natural
Products Association asserted, “If the FTC intends to depart from
its traditional competent and reliable scientific evidence standard,
then new formal guidance is necessary.” 79 The FTC rejected the
concerns in each of these public comments, clarifying that “[t]he
optimal amount and type of evidence to substantiate a future claim
will vary from case to case.”80
In the L’Oréal decision and order, the Commission did not
mandate that the company have two random clinical trials to
substantiate its claims for its Lancôme Génifique and L’Oréal Paris
Youth Code skincare products. 81 Rather, the FTC indicated that
L’Oréal must have “competent and reliable scientific evidence”82
77
Order at 4, In re GeneLink, Inc. & Foru Int’l Corp., No. 112-3095 (F.T.C.
May 8, 2014). Well controlled studies are defined in the consent order as:
[A] human clinical study that: is randomized and adequately controlled;
utilizes valid end points generally recognized by experts in the relevant
disease field; yields statistically significant between-group results; and is
conducted by persons qualified by training and experience to conduct such
a study. Such study shall be double-blind and placebo-controlled . . . .
Id. at 2.
78
Letter from Donald S. Clark, Sec’y, Fed. Trade Comm’n, to Rend
Al-Mondhiry, Esq., Regulatory Counsel, Council For Responsible Nutrition
(May 8, 2014) available at http://www.ftc.gov/system/files/documents/cases/
140512genelinkcouncilletter_0.pdf.
79
Letter from Donald S. Clark, Re: Genelink, Inc., & Foru™ Int’l Corp FTC
File No. 112-3095 and Docket Nos. C-4456 and C-4457 (May 8, 2014), available at
http://www.ftc.gov/system/files/documents/cases/140512genelinknaturalletter_0.pdf.
80
Joshua D. Wright, Statement of Comm’r Joshua D. Wright, FED. TRADE
COMM’N (Jan. 7, 2014), available at http://www.ftc.gov/system/files/documents/
public_statements/567801/140107genelinkstatement.pdf.
81
Order at 1, In re L’Oréal USA, Inc., No. 122-3016 (F.T.C. Sept. 24, 2014).
82
Id. at 2. “Competent and reliable scientific evidence shall mean evidence,
consisting of tests, analyses, research, or studies that have been conducted and
evaluated in an objective manner by qualified persons and are generally
accepted in the profession to yield accurate and reliable results.” Id.
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before claiming that any of its products can affect gene activity or
growth.83
The FTC clarified three main takeaways from the L’Oréal
decision. 84 First, when advertisers claim that “studies show,” or
“doctors recommend,” advertisers must have at least the level of
substantiation purported in the advertisement.85 Second, the support
for the product must be “fit to be tried.”86 Third, “once companies
make objective product representations, long standing substantiation
principles apply.” 87 These principles apply to other DTC genetic
testing companies claiming that their products affect genes.
D. Genetic Information Nondiscrimination Act
The Genetic Information Nondiscrimination Act (“GINA”) 88
prevents employers and health insurance companies from
discriminating based on genetic information. 89 This act offers
protection to consumers from the unauthorized use of their DTC
genetic test results.90
In 2013, the Equal Opportunity Employment Commission
(“EEOC”) settled its first lawsuit alleging violations of the Genetic
Information Nondiscrimination Act. 91 The EEOC found that
Fabricut, Inc. (“Fabricut”), one of the world’s largest distributors
of decorative fabrics, violated GINA when it requested prohibited
83

Id. at 3.
Lesley Fair, FTC to L’Oreal: Scientific Claims Need Proof that’s More than
Just Skin Deep, BUS. CTR. BLOG, http://business.ftc.gov/blog/2014/06/ftc-lorealscientific-claims-need-proof-thats-more-just-skin-deep (last updated June 30, 2014).
85
Id.
86
Id.
87
Id.
88
Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233,
122 Stat. 881 (2008).
89
Genetic Testing, GENETICS HOME REFERENCE, http://ghr.nlm.nih.gov/handbook/
testing?show=all#genetictesting (last updated Nov. 11, 2014) (explaining that
Title I prevents genetic discrimination in health insurance, and Title II prevents
genetic discrimination by employers).
90
Su, supra note 5, at 361.
91
Fabricut to Pay $50,000 to Settle EEOC Disability and Genetic Information
Discrimination Lawsuit, U.S. EQUAL EMP’T OPPORTUNITY COMM’N, http://
www.eeoc.gov/eeoc/newsroom/release/5-7-13b.cfm (last updated May 7, 2013).
84
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family medical history in its post-offer medical examination.92 On
May 7, 2013 Fabricut agreed to pay $50,000 and to take action to
prevent future discrimination.93
Barbara Seely, EEOC Regional Attorney, noted that many
employers still do not understand that requesting family medical
history is prohibited.94 Additionally, according to a 2010 study, less
than 20% of the adult population in Connecticut, Michigan, Ohio
and Oregon had knowledge of genetic non-discrimination laws,
while 80% perceived that these laws were very or somewhat
important. 95 Over two-thirds were concerned with insurance
companies using genetic test results to determine life insurance
coverage and costs. 96 This study suggests that further public
education is necessary to raise awareness of the protections
provided by current genetic nondiscrimination laws.97
While GINA creates additional safeguards through genetic
nondiscrimination by health insurance companies and by
employers, GINA is silent on a number of issues.98 For example,
GINA does not bar genetic discrimination outside the health
insurance and employment contexts, and does not address concerns
92

Id. Fabricut required Rhonda Jones to fill out a questionnaire and disclose
separately listed disorders in her family medical history. Although Jones
indicated in the questionnaire that she did not have Carpal Tunnel Syndrome
(CTS), Fabricut required her to submit to further testing. Fabricut’s contract
medical examiner, Knox Laboratories, found that Jones did have CTS, and
Fabricut rescinded her application. The EEOC found that Fabricut engaged in
illegal conduct when it discriminated against Jones based on genetic
information–which includes family medical history. Id.
93
Id.
94
Id.
95
Alicia A. Parkman et. al., Public Awareness of Genetic Nondiscrimination
Laws in Four States and Perceived Importance of Life Insurance Protections, J.
GENETIC COUNSELING 1, 4–6 (2014), available at http://www.ncbi.nlm.nih.gov/
pubmed/25242499.
96
Id.
97
Id. at 7.
98
Colin McFerrin, DNA, Genetic Material, and A Look at Property Rights:
Why You May Be Your Brother's Keeper, 19 TEX. WESLEYAN L. REV. 967, 984
(2013) (citing Elizabeth E. Joh, DNA Theft: Recognizing the Crime of
Nonconsensual Genetic Collection and Testing, 91 B.U. L. Rev. 665, 686
(2011)).
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surrounding abandoned DNA or the nonconsensual collection and
testing of genetic material. 99 Additionally, GINA only covers
asymptomatic individuals as compared to state insurance laws
which cover symptomatic individuals.100 Moreover, GINA does not
indicate how DTC genetic tests should be interpreted and
communicated.101
Although GINA was enacted in 2008, the EEOC only started
enforcing the law in 2013. 102 However, the EEOC has indicated
that it plans to enforce GINA against employers, by also settling an
action against Founders Pavilion, Inc. in early 2014. 103 David
Lopez, EEOC General Counsel, commented that illegal questions
will not be tolerated and the “EEOC will be vigilant in ensuring
that no one is denied employment opportunities on a prohibited
basis.” 104 Furthermore, the EEOC stated that addressing genetic
discrimination is one of the six national priorities of the EEOC’s
Strategic Enforcement Plan.105
E. State Laws: Further Complications or a Model for the Future?
Further complicating matters, various state laws govern the
status of DTC genetic tests. Twenty-five states,106 including New
York 107 and California, 108 have passed statutes or regulations that
99

Id. at 985.
Id. (citing Mark A. Rothstein, GINA's Beauty is Only Skin Deep, GENEWATCH,
http://www.councilforresponsiblegenetics.org/GeneWatch/GeneWatchPage.aspx
?pageId=184 (last visited Mar. 3, 2013)).
101
Michelle D. Irick, Age of an Information Revolution: The Direct-to-Consumer
Genetic Testing Industry and the Need for A Holistic Regulatory Approach, 49
SAN DIEGO L. REV. 279, 290 (2012).
102
Founders Pavilion Will Pay $370,000 to Settle EEOC Genetic Information
Discrimination Lawsuit, U.S. EQUAL OPPORTUNITY EMP’T COMM’N, http://
www.eeoc.gov/eeoc/newsroom/release/1-13-14.cfm, (last updated Jan. 13, 2014).
103
Id.
104
Id.
105
Id.
106
GENETICS & PUB. POLICY CTR., JOHNS HOPKINS UNIV., SURVEY OF
DIRECT-TO-CONSUMER TESTING STATUTES AND REGULATIONS 1-14 (2007),
available at http://www.dnapolicy.org/resources/DTCStateLawChart.pdf [hereinafter
DTC Testing Survey].
107
See, e.g., N.Y. PUB. HEALTH LAW § 576-b(1) (2002) (requiring that any clinical
laboratory services be FDA approved); N.Y. PUB. HEALTH LAW § 577 (2011);
100
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specifically restrict or prohibit DTC genetic testing.109 Accordingly,
observers fear that “conflicts between the laws of various states,
and between state and federal law, will increase legal and
regulatory uncertainty.” 110 The variety in state laws regarding
genetic testing could serve to fuel further confusion about the
legality of DTC genetic testing.
However, some states could serve as models for other states’
genetic testing and privacy laws, or as a model for the federal
government to follow. For example, Alaska’s Genetic Testing
Statute is more comprehensive than GINA. 111 The Alaska statute
provides a private cause of action against individuals who analyze,
collect, or retain DNA samples without consent, or individuals that
release the results of DNA testing.112 The statute requires written
consent before a person can collect, analyze, retain, or disclose an
individual’s DNA analysis results.113
Three other states, Colorado, Florida, and Georgia, also declare
genetic information to be the private property of the individual to
which it pertains.114 The Colorado and Georgia statutes are in each
state’s insurance code, and prohibit the unauthorized testing and
disclosure, and discrimination of individuals’ DNA for insurance
10 NYCRR 19.1(j) (2014); 10 NYCRR 58-1.7 (2014); 10 NYCRR § 58-1.8 (2014);
10 NYCRR § 63.3(e) (2014).
108
See, e.g., CAL. BUS. & PROF. CODE § 1246.5 (2005) (providing that “[t]he
tests that may be conducted pursuant to this section are: pregnancy, glucose
level, cholesterol, occult blood, and any other test for which there is a test for a
particular analyte approved by the federal Food and Drug Administration for
sale to the public without a prescription in the form of an over-the-counter test
kit”).
109
Alabama, Connecticut, Georgia, Hawaii, Idaho, Kentucky, Michigan, New
Hampshire, Pennsylvania, Rhode Island, South Carolina, Tennessee, and
Wyoming specifically prohibit DTC genetic testing; Arizona, California,
Colorado, Florida, Illinois, Maine, Maryland, Massachusetts, Nevada, New
Jersey, New York, and Oregon limit DTC genetic testing. DTC Testing Survey,
supra note 106.
110
Id.
111
McFerrin, supra note 98, at 986.
112
ALASKA STAT. § 18.13.010 (2004).
113
Id.
114
SETH AXELRAD, STATES DECLARING GENETIC INFORMATION TO BE PERSONAL
PROPERTY (2005), available at https://www.aslme.org/dna_04/reports/axelrad4.pdf.
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purposes.115 The Colorado and Georgia statutes also establish civil
remedies when insurers engage in unfair practices based on the use
of DNA.116 Florida and Alaska, on the other hand, both establish
criminal penalties for misuse of genetic information, 117 which
might serve to more effectively deter the misappropriation of
genetic information. These state statutes—all arguably more
comprehensive than GINA—might not only serve to create a more
confusing framework for DTC genetic testing companies; rather,
they may actually serve as a model for future amendments to
GINA and demonstrate how the EEOC might go about enforcing
the Act against a DTC genetic testing company under GINA.
F. Association for Molecular Pathology v. Myriad Genetics, Inc.:
Implications to DTC Genetic Testing Companies
The Supreme Court in Association for Molecular Pathology v.
Myriad Genetics, Inc.118 removed a potential barrier to large-scale
DTC genetic testing and genomic sequencing 119 because the
holding limited the patentability of human genetic material. The
Supreme Court held that “a naturally occurring DNA segment is a
product of nature and not patent eligible merely because it has
been isolated.”120 Moreover, research indicates that limiting genetic
patents will continue to allow the DTC industry to flourish.121 For
example, one study found that patents do not appear to be
115
COLO. REV. STAT. § 10-3-1104.7(1)(a) (2009); GA. CODE ANN. § 33-54-1(1)
(1995).
116
Axelrad, supra note 114; COLO. REV. STAT. § 10-3-1104.7(11) (2009); GA.
CODE ANN. § 33-54-8 (1995).
117
FLA. STAT. § 760.40(2)(a) (2009); ALASKA STAT. § 18.13.010(a)-(b) (2004).
118
133 S. Ct. 2107 (2013).
119
Spector-Bagdady & Pike, supra note 14, at 683.
120
Myriad, 133 S. Ct. at 2111.
121
Fifty-nine percent of the nation’s basic genetic research is federally funded,
and therefore patents are not necessary for much of basic research to occur. U.S.
DEP'T OF HEALTH & HUMAN SERVS., GENE PATENTS AND LICENSING PRACTICES
AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS: REPORT OF THE
SEC'YS ADVISORY COMM. ON GENETICS, HEALTH, & SOC'Y, 2 (Apr. 2010),
available at http://osp.od.nih.gov/sites/default/files/SACGHS_patents_report_2010.pdf
(citing Science and Engineering Indicators 2008, NAT’L SCIENCE FOUND.,
http://www.nsf.gov/statistics/seind08/c4/c4h.htm#c4hs (last visited Oct. 20, 2014)).
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necessary to promote genetic research or to develop genetic tests.122
The study also indicated that the prospect of patenting a genetic
research discovery does not play a significant role in motivating
scientific research.123
Despite Myriad’s holding that naturally occurring sequences of
DNA are not patentable,124 other DTC genetic testing companies,
like 23andMe, Inc. (“23andMe”), currently hold patents related to
naturally occurring DNA sequences. 125 For example, 23andMe’s
first patent “Polymorphisms Associated with Parkinson’s Disease,”
which relates to the discovery of a “variation in the SGK1 gene
that may be protective against Parkinson’s disease in individuals
who carry the rare risk-associated LRRK2 G2019S mutation,” seems
extremely similar to Myriad’s patents of the BRCA1 and BRCA2
genes that were struck down in Myriad.126 It is theoretically possible
that 23andMe’s patent could be struck down under a similar theory
as the Myriad decision came out after the 23andMe patent was
submitted.
However, it is unlikely that gene patents will disappear
post-Myriad. 127 Inventors could utilize trade secret protection,
although there is a risk another inventor could come up with the
same invention and the original inventor would lack the legal tools
to prevent the competitor from profiting from the invention.128 An
122

U.S. DEP'T OF HEALTH & HUMAN SERVS., supra note 121, at 2.
Id.; John M. Golden, Biotechnology, Technology Policy, and Patentability:
Natural Products and Invention in the American System, 50 EMORY L.J. 101,
153–54 (2001) (describing that scientists are primarily motivated by idealistic
desires like “contributing to scientific and technological progress.”).
124
Myriad, 133 S. Ct. 2107, 2115–20 (2013) (holding “[a] naturally occurring
DNA segment is a product of nature and not patent eligible merely because it
has been isolated, but cDNA is patent eligible because it is not naturally
occurring.”).
125
Announcing 23andMe’s First Patent, 23ANDME BLOG (May 28, 2012),
http://blog.23andme.com/news/announcements/announcing-23andmes-first-patent/.
126
See id. (referring to the Myriad case ruling in which Myriad’s proposed
patent was a genetic patent like 23andMe’s).
127
Jessica L. Marks, et al., Gene Patents Won’t Disappear Post-Myriad, LAW360
(July 22, 2013), http://www.finnegan.com/resources/articles/articlesdetail.aspx?
news=b4a7795a-bee4-431a-bab2-47ee02ea5608.
128
Id.
123
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inventor could also attempt to patent isolated nucleic acids rather
than straightforward, complementary DNA, 129 which the court
stated is not naturally occurring.130 DTC genetic testing companies
could continue to “get around” the loophole that naturally
occurring DNA sequences are not patentable. The Myriad decision
will continue to affect the DTC industry as various companies are
allowed to compete with one another to find the best SNP131 sites to
conduct genetic tests, or as the companies discover new SNP sites
with the potential for predicting health risks.
G. Tompkins v. 23andMe Inc. and Regulatory Repercussions
A case recently decided in the Northern District of California,
Tompkins v. 23andMe Inc., 132 involved a class action related to
defendant 23andMe’s advertising and marketing of its Personal
Genome Service. 133 23andMe’s “FDA takedown” last November
might have influenced some lawyers to “move in for their cash
grab,” demonstrating how regulatory decisions can sometimes
prompt litigation. 134 The primary issue between the parties arose
129

Id.
Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct.
2107, 2107 (2013).
131
Single Nucleotide Polymorphism or SNP, supra note 11 and
accompanying text.
132
5:13-CV-05682-LHK, 2014 WL 2903752, at *1 (N.D. Cal. June 25, 2014).
133
Id. (“PGS is a service that consists of a DNA saliva collection kit (‘DNA kit’)
and DNA test results with certain genetic information derived from a consumer's
saliva sample.”)).
134
Linda A. Willett, Litigation As an Alternative to Regulation: Problems
Created by Follow-on Lawsuits with Multiple Outcomes, 18 GEO. J. LEGAL
ETHICS 1477, 1482 (2005) (“During the past few years, when the FDA has used
its technical review process to challenge language, photos, or footage in a DTC
advertisement, a series of private lawsuits, now known as ‘follow-on’ actions,
has quickly followed. For example, an FDA decision to require withdrawal of
DTC advertising may be followed by one or more federal and state court
actions, including class action suits brought under broadly written state
consumer protection laws by those purporting to represent the citizens of a state.
Some of these actions are without merit and ultimately result in nothing more
than a drain on the court system.”); Eric Goldman, 23andMe’s Browsewrap
Fails, But It’s Post- Purchase Clickthrough Works Anyway—Tompkins v. 23andMe,
TECH. & MKTG. LAW BLOG (July 2, 2014), http://blog.ericgoldman.org/archives/
130
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out of the arbitration provision in the Terms of Service (section
28(b)) in the miscellaneous section). 135 The California court
dismissed the plaintiffs’ class action claims, with 23andMe
defending an arbitration agreement 136 consumers signed in the
company’s Terms of Service (“TOS”).137
The court found that the method of accepting the TOS
resembled “clickwrap agreements, where an offeree receives an
opportunity to review terms and conditions and must affirmatively

2014/07/23andmes-browsewrap-fails-but-its-post-purchase-clickthrough-worksanyway-tompkins-v-23andme.htm.
135
Tompkins, 2014 WL 2903752 at *2.
136
Id. at *1. The arbitration agreement read as follows:
Applicable law and arbitration. Except for any disputes relating to
intellectual property rights, obligations, or any infringement claims, any
disputes with 23andMe arising out of or relating to the Agreement
(“Disputes”) shall be governed by California law regardless of your country
of origin or where you access 23andMe, and notwithstanding of any
conflicts of law principles and the United Nations Convention for the
International Sale of Goods. Any Disputes shall be resolved by final and
binding arbitration under the rules and auspices of the American Arbitration
Association, to be held in San Francisco, California, in English, with a
written decision stating legal reasoning issued by the arbitrator(s) at either
party's request, and with arbitration costs and reasonable documented
attorneys’ costs of both parties to be borne by the party that ultimately
loses. Either party may obtain injunctive relief (preliminary or permanent)
and orders to compel arbitration or enforce arbitral awards in any court of
competent jurisdiction.
Id. at *2.
137
During the account creation and registration processes, each named
Plaintiff clicked a box near a hyperlink to indicate acceptance of the terms of
service. Id. at *3. 23andMe argued that it was “impossible to register for and
receive the Service without clicking ‘I ACCEPT’ to the TOS.” Id. at *6 (internal
quotations omitted). However, the court held that because the only way
consumers could see the TOS at the time of purchase was to scroll to the bottom
of the screen, a better practice would be to show or require acknowledgement of
such terms at the point of sale. Id. at *7. Therefore, the court held that
23andMe’s TOS would have been ineffective to bind website visitors or
consumers who purchased a DNA kit without creating an account or registering
a kit. Id. After the consumers made the purchase, in order to get the results, they
had to accept the terms of service by clicking a button that appeared near a
hyperlink of the terms of service. Id. at *8.
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indicate assent.” 138 However, the court’s reasoning here is
unsatisfying for two reasons. First, the court ignores the possibility
of a consumer buying the service for another party (like a minor or
a friend) and second, the court does not take into account economic
realities because at that point the consumer cannot receive a full
refund for their results.139 While the court acknowledges that it is
possible for a consumer to buy the DNA kit as a gift for someone
else without creating an account or registering the kit, the court
moves on without addressing this potential issue. 140 If someone
were to purchase the kit as a gift for a minor or third party, his or
her autonomy and privacy concerns might not be addressed.
The court held that although the terms of service were
hyperlinked and not on the same screen, the consumers still had
adequate notice of the terms of service. 141 Although the court
ultimately upheld the arbitration clause in the agreement and
dismissed the case without prejudice, 142 the plaintiffs have the
opportunity to appeal to the Ninth Circuit.143
While consumer freedom to purchase these products is
important, agencies like the FTC should work with other
regulatory bodies (including the FDA, CMS under the CLIA, and
various state agencies) to draft better procedures to allow
consumers to fully understand the terms of service. In this case,
one of the most reputable genetic testing companies arguably
138

Id. at *8.
Goldman, supra note 134.
140
Tompkins, 2014 WL 2903752 at *3.
141
Id. at *8. The plaintiffs finally argued that the arbitration agreement in the
TOS was unconscionable. Id. at *9. The court agreed that the clause was
procedurally unconscionable because 23andMe’s website provided minimal notice
of the TOS to consumers. Id. at *14. Additionally, the clause is a standardized
clause presented as a take-it-or-leave-it agreement, leaving consumers without
any negotiating power. Id. at *15. The court held that the arbitration agreement
was not substantively unconscionable. Id. The court held that 23andMe’s
headquarters as the arbitration forum, a carve out for claims by 23andMe, and
limitations of legal remedies were “not so unduly harsh or one-sided” to become
substantively unconscionable. Id. at *16.
142
Id. at *18.
143
The case could become “a flagship cyberlaw case.” Goldman, supra note
134.
139
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“obscured the terms of service” in an “unfair way.” 144 Protecting
consumers from this type of behavior is squarely in the realm of
the FTC, whose mission is to help protect consumers from
deceptive and unfair business practices.145
III. IMPLICATIONS AND RECOMMENDATIONS
This part analyzes how a genetic service like Interleukin Inc.’s
“Inherent Health” might be regulated under the current regulatory
framework. Each of the various regulatory stakeholders, including
the FDA, FTC, CLIA, GINA, state genetic testing statutes, and the
Tompkins decision might become relevant for Interleukin. The
FTC should enforce regulations against this particular type of
genetic testing service, informed by heightened CLIA standards.
A. Inherent Health: Different than 23andMe Under FDA
Regulation?
Interleukin Genetics, Inc., a personalized health company,
introduced Inherent Health™ in 2009. 146 Inerleukin’s Inherent
Health product includes genetic tests for heart health, weight
management, nutritional needs, and bone health, among others.147
Interleukin was among the DTC genetic testing companies that
received untitled letters 148 in 2010 because the FDA had not
preapproved Inherent Health. 149 However, since that letter, the
144

Tompkins, 2014 WL 2903752 at *7.
About the FTC, FED. TRADE COMM’N, http://www.ftc.gov/about-ftc (last
visited Sept. 26, 2014).
146
About Interleukin Genetics, INTERLEUKIN GENETICS, http://www.ilgenetics.com/
content/about-interleukin (last visited Nov. 1, 2014).
147
Our Genetic Tests, INTERLEUKIN GENETICS, http://www.inherenthealth.com/
our-tests.aspx (last visited Nov. 1, 2014).
148
“Unlike a warning letter, an untitled letter does not include a statement that
warns the individual or firm that failure to correct the violation may result in
enforcement action.” U.S. FED. DRUG ADMIN, WARNING AND UNTITLED LETTERS 1
(2011) available at http://www.fda.gov/downloads/AboutFDA/Transparency/
PublicDisclosure/GlossaryofAcronymsandAbbreviations/UCM212064.pdf (last
visited Nov. 20, 2014).
149
Letter from James Woods, Deputy Dir., Patient Safety and Product
Quality, Office of In Vitro Diagnostic Device Evaluation and Safety, Ctr. for
Devices & Radiological Health, to Lewis H. Bender, CEO, Interleukin Genetics,
145
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FDA has not taken further action against the company. The FDA
probably does not think that Inherent Health posed much of a risk
to consumers because its genetic test sales have been slipping.150
For example, in 2013 Inherent Health received a much needed $12
million injection of capital into its business to “prolong its
survival.” 151 Additionally, Interleukin Genetics never intended to
sell its brand in national stores like Walgreens like Pathway
Genomics, nor has it attempted a nationwide televised advertising
campaign like 23andMe.152 Like all agencies, the FDA has limited
resources and a finite budget.153 Attempting to enforce regulations
against every single DTC genetic testing company, however small,
might not be the best utilization of these resources.
DTC genetic testing companies like Interleukin should make
sure to stay in contact with the FDA if they ever receive a warning
letter. The FDA issued a harsh rebuke to 23andMe because the
company essentially stopped communicating with the FDA for
eleven months without completing the certification for its tests and
planned an aggressive new marketing campaign.154 If 23andMe had
been more forthcoming with the FDA, the agency might not have
needed to resort to such harsh measures.
To be sure, 23andMe arguably offered a better, more reliable
product than Interleukin Genetics currently does. While Interleukin
Genetics claims that its Inherent Health product is supported by
various studies, some argue that companies like Interleukin

Inc. (July 19, 2010), available at http://www.fda.gov/downloads/MedicalDevices/
ProductsandMedicalProcedures/InVitroDiagnostics/UCM219587.pdf.
150
See Mark Hollmer, Interleukin Genetics Raises $12M in Last-Ditch Save,
FIERCE MEDICAL DEVICES (May 20, 2013), http://www.fiercemedicaldevices.com/
story/interleukin-genetics-raises-12m-last-ditch-save/2013-05-20.
151
Id.
152
See supra notes 20–21 and accompanying text.
153
John Lehmann, Budget Constraints Impacting FDA Strategic Priorities,
IMARC RESEARCH (July 25, 2014 6:48 AM), http://www.imarcresearch.com/
blog/bid/351768/Budget-Constraints-Impacting-FDA-Strategic-Priorities.
154
See Warning Letter to Wojcicki, supra note 21.
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Genetics, among others, are bringing the industry down by
marketing suspect tests.155
Perhaps Interleukin is the type of company the FDA should be
regulating. The FDA should worry about the unreliability of the
“weight loss management product” 156 from Interleukin. 157 DTC
genetic test critics already fear that science cannot offer certainty
based on a predictive DTC genetic test. 158 Few resources are
available to gauge the reliability of the DTC genetic tests. 159
Furthermore, each test varies according to the specific SNP sites
analyzed by the test and the capabilities of the individual lab
performing the test.160
Studies have questioned the reliability of DTC genetic tests.
For example, the GAO has conducted a number of investigations
and other oversight activities related to DTC genetic testing.161 A
2006 GAO investigation of four companies selling DTC genetic
tests found that these companies “misled consumers by providing
test results that were both medically unproven and so ambiguous as
to be meaningless.”162 In 2008, the Secretary’s Advisory Committee
on Genetics, Health, and Society discovered that there were
significant gaps related to the oversight of genetic testing in five

155

See Helen Wallace, Misleading Marketing of Genetic Tests, Will the
Genome Become the Source of Diagnostic Miracles or Potential Scams?
COUNCIL FOR RESPONSIBLE GENETICS, http://www.councilforresponsiblegenetics.org/
ViewPage.aspx?pageId=88 (last visited Oct. 30, 2014).
156
Inherent Health advertises weight loss solutions tailored to your genes on
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areas.163 Two years later, the GAO concluded that these tests were
still “misleading” and “yielded contradictory predictions.”164 Although
these DTC genetic tests might have some scientific validity, 165
Inherent Health may be among the genetic testing products with
unproven and misleading claims.
B. The FTC: Is Inherent Health “Fit to be Tried?”
The FTC should regulate companies like Interleukin.
Interleukin’s Inherent Health tells consumers, “Don’t waste a day
on the wrong diet! The Weight Management Genetic Test may
help you lose more weight by properly matching diet and exercise
to your personal genotypes. No guessing!” 166 While Interleukin’s
Inherent Health may have validity as a CLIA certified testing
company, this type of blanket statement might simply confuse
consumers who will believe that a genetic test holds the key to
their weight loss.167 Because Inherent Health claims to be “CLIA
certified,” there seems to be a discrepancy between the high

163
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(1) the regulations governing clinical laboratory quality; (2) oversight of the
clinical validity of genetic tests; (3) the transparency of genetic testing; (4)
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and (5) the educational needs of health professionals, the public health
community, patients and consumers.
Spector-Bagdady & Pike, supra note 14, at 694 (internal quotations omitted).
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important. It shows that we are nowhere near really being able to interpret [such
tests].” Id. at 8.
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See Schleckser, supra note 60, at 712 (arguing that the GAO’s conclusions
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standards promulgated by other government agencies, and the
claims this company is making.
Inherent Health seems to validate concerns that the FTC
warned against in the L’Oréal matter and the Genelink foru™
matter. For example, Inherent Health claims: “Finally—the
answers you need to get results faster, stay confident and
motivated, and take control of your weight. Order today!” 168
Interleukin claims that these conclusions are based on a study,
partly funded by the company itself.169 However, it is unclear if this
single study would meet the FTC’s standard that “once companies
make objective product representations, long standing
substantiation principles apply.”170 Inherent Health also has a report
“showing the science behind the test.”171 The “Science Behind the
Weight Management Genetic Test” demonstrates how the
company came to the conclusion that five variations in four genes
impact various pathways that influence body weight and have a
related risk for obesity. 172 Because the company substantiated its
decision to test those particular genes with multiple scientific
studies, it is unclear whether this method would be enough to
survive the FTC’s standard that the product must be “fit to be
tried.”173 Additionally, “The Science Behind the Weight Management
Genetic Test” might be too jargon-heavy and inaccessible for the
168
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average consumer attempting to verify that the test is scientifically
accepted. The FTC should make sure that the tests are
(1) supported by substantial evidence, and (2) consumers can
understand that these studies are valid.
C. Make CLIA Certification Meaningful
Interleukin’s Inherent Health also demonstrates that CLIA
should be doing more to regulate these DTC genetic testing
companies. The “CLIA certified” 174 label on the Inherent Health
product might convince consumers that the product is reliable. The
Interleukin Genetics lab in Waltham, Massachusetts has achieved a
CLIA “Certificate of Compliance.” 175 This CLIA certification
seems to be in contradiction with the FDA’s 2010 letter expressing
concern about Interleukin’s DTC genetic testing and the FTC’s
stance on DTC genetic testing. A better practice would be to make
sure that a company in compliance with one of the federal
regulatory mechanisms is in compliance with all of them; it is
misleading to consumers to say that it is certified by one federal
regulatory mechanism but not another.
D. GINA and State Genetic Testing Statutes: A Privacy Paradigm
DTC genetic testing opponents are concerned about a
consumer’s privacy after these consumers purchase the Inherent
Health product. 176 Specifically, critics are concerned with what
174
There are five different CLIA Certificates including: Certificate of Waiver;
a certificate for microscopy procedures; a certificate of registration for midlevel
or high complexity tests; a certificate of compliance after inspection; and a
certificate of accreditation on the basis of an accreditation organization approved
by the Healthcare Financing Administration. CTRS. FOR MEDICARE AND
MEDICAID SERVS., TYPES OF CLIA CERTIFICATES 1 (2003), available at
https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/downloads/
TYPES_OF_CLIA_CERTIFICATES.pdf (last visited Nov. 11, 2014).
175
22D1038543 CLIA Number - Interleukin Genetics, Inc., HEALTH PROVIDERS
DATA http://healthprovidersdata.com/hipaa/codes/CLIA_22D1038543.aspx (last
visited Nov. 11, 2014).
176
See Lauren B. Solberg, Over the Counter but Under the Radar: Direct-toConsumer Genetics Tests and FDA Regulation of Medical Devices, 11 VAND. J.
ENT. & TECH. L. 711, 721 (2009) (“Although genetic testing services may
inform consumers that their genetic material or information may be sold to third
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should and will happen to genetic testing information from
minors. 177 Despite critics’ fears, companies like Interleukin
Genetics do expressly address the issues associated with genetic
testing information from minors. For example, Interleukin’s
Inherent Health privacy policy specifically indicates, “Our Website
is not intended for, or designed to attract, children under the age of
13.”178
The Interleukin privacy policy also explains that the company
utilizes several different procedures to protect a client’s personal
information, including using assigned usernames and passwords,
anonymous barcodes for DNA, server firewalls, and an encrypted
website.179 Interleukin also specifically acknowledges GINA under
a section entitled “Federal Laws Protecting You.”180 The company
explains that a consumer is not required to share the genetic
information with an insurer or an employer.181 The company also
explains that there are “state laws that prevent insurers, employers,
and others from using genetic tests for discriminatory purposes,”
depending on the state.182 While consumers would have to read the
privacy policy to find the information that could potentially
address their privacy concerns, the policy seems relatively
comprehensive to help educate consumers about their privacy
rights.

parties and used for research purposes, questions arise as to whether individuals
are aware of this practice and understand he ramifications of consenting to this
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E. Interleukin Genetics, Tompkins, and Consumer Autonomy
Concerns related to DTC Genetic Testing
Like in 23andMe v. Tompkins, Interleukin’s terms of use might
be obscured in an unfair way. 183 In order to sign up for a new
account on Interleukin’s website, one must create a user name,
password, and fill out your email with a security question and
security answer.184 Next, a consumer must certify that they are at
least eighteen years old and they agree to comply with
Inherenthealth.com’s terms of use. 185 The terms of use are
hyperlinked to another page. 186 Interleukin does not require a
consumer to acknowledge the terms of service after creating an
account in order to purchase the product. This formulation seems
similar to 23andMe’s former practice, which might give rise to
similar criticisms. 187 Theoretically, a third party could use the
account to purchase the product without ever seeing the terms of
service. A better practice would be for a consumer to acknowledge
the terms again at the time of purchasing the product.188
The terms of use also indicate service limitations, including a
recommendation that consumers discuss any health-related
findings with a physician or health care professional regarding the
diagnosis, prevention, or treatment of a condition. 189 Interleukin
also does not warrant that the information on the website,
including information about the products actually offered, is
completely accurate and current, including information about the
products actually offered. 190 These terms of use highlight the
arguments in favor of a role for a learned intermediary, such as a
physician, in the interpretation of the genetic test results.
183
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Without the help of physician interpretation, consumers who
receive their genetic tests from a company like Interleukin could
misunderstand the results—a misunderstanding that could lead to
severe psychological trauma.191 It could be traumatic to learn that a
DTC genetic test predicts an increased risk for diseases such as
Alzheimer’s or Huntington’s, which are incurable or have limited
treatment options. 192 While Interleukin is selling health-related
genetic tests, these tests are related to weight management and
nutrition, and none purport to predict disease risks.193 These types
of tests seem more analogous to various weight loss apps like
“MyFitnessPal,” where users can track their weight, calorie intake,
and exercise habits. 194 While users could and perhaps should
consult with physicians regarding their weight, exercise, and other
habits, ultimately the decisions to exercise or eat certain foods
should be left to the individual.
Furthermore, genetic counseling for consumers who wish to
seek advice to better inform their decisions may be prohibitively
expensive.195 For example, 23andMe offered genetic counseling for
a price range of $99 to speak to a genetic counselor, and up to
$250 to have “comprehensive” clinical genetic counseling. 196
191
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physicians in the genetic test interpretation process could exacerbate privacy
concerns).
192
Solberg, supra note 176, at 720.
193
See inherenthealth.com, supra note 156.
194
Parmy Olson, MyFitnessPal Starts Tracking Steps to Grow The World’s Largest
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Geneticists and medical professionals maintain that this limited
counseling available from the companies is inadequate because the
company providing the counseling has an interest in selling more
tests.197
In addition, while consumers might misunderstand the results
of their genetic tests from companies like Interleukin; patients
might also misunderstand any type of diagnosis from their doctor,
or the results from any other medical test. While there is always a
chance of miscommunication, the vast majority of consumers are
interpreting their results correctly. 198 Evidence also conflicts with
critics’ fears that consumers who learn they have an increased risk
for certain diseases might take extreme actions. 199 Many DTC
genetic test consumers understand there are many variables
influencing the risk of disease.200
Based on this information, it is clear that many consumers can
understand the results of the genetic test itself, but that it might be
best to involve a physician to ensure that consumers are
interpreting their results correctly and take the best course of action
regarding their results. Involvement of medical professionals could
impede the autonomy some patients might value from DTC genetic
testing,201 but some individuals are using these DTC genetic tests to
make a significant medical decision based on their health risks for
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serious conditions like Huntington’s or Alzheimer’s.202 Therefore,
physician involvement might outweigh autonomy concerns when
interpreting results for incurable diseases, but not for companies
like Interleukin that provide weight-loss plans.
G. Bringing the Regulatory Framework Together for Interleukin
Genetics
Perhaps Interleukin Genetics will stay off the FDA’s radar
because its consumer base is relatively small in comparison to
other DTC genetic testing companies. However, if Interleukin
makes major marketing plans or stops communicating with the
FDA regarding any key changes, the company should expect to be
sanctioned similarly to 23andMe. The FDA has indicated its
displeasure at being kept out of the loop.203 Silicon Valley start-ups
and genetic researchers might not be as concerned with regulatory
agencies in Washington when their goals include innovating
toward the future. However, the agency’s decision to curtail
23andMe’s health-related Personal Genome Service has sent
shockwaves through the industry, and other companies offering
health-related products should pay attention. Some speculate
23andMe’s recent negative experience is why Apple’s new
“HealthKit” update was released without much fanfare.204
The FTC seems to be the natural choice to enforce regulations
against Interleukin and expose whether the company is misleading
consumers or making unsubstantiated claims about the Inherent
Health product. The FTC’s recent enforcements against Genelink
and L’Oreal indicate that the agency is willing to put companies to
the test to make sure their products are “fit to be tried.”
202
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In order to make sure that Interleukin is consistently able to
make health-related claims credibly, CLIA certification needs to
mean something more. A CLIA certification should indicate that
laboratories are clinically and analytically valid to be useful to
potential consumers. Systematic gaps in the oversight of these
laboratories need to be addressed. If a laboratory is CLIA certified,
the FDA and the FTC should not indicate that the genetic tests are
unreliable.
State genetic testing statutes and GINA should serve to
ameliorate consumer concerns about privacy. The Tompkins v.
23andMe decision should inform Interleukin and other DTC
genetic testing companies about the appropriate ways to formulate
their terms of use. The Myriad decision should remind genetic
testing companies and Interleukin that patenting a natural DNA
sequence will not withstand a reviewing court’s scrutiny. Genetic
testing companies should be regulated in a way that allows for
innovation.
IV. CONCLUSION
Despite the obvious limitations and shortcomings of the current
DTC testing market, the current regulatory framework might
inhibit future innovation rather than save consumers from
themselves. For example, 23andMe’s fight to go forward with
premarket approval for one test demonstrates how the company’s
battle with the FDA will be long and time-consuming. 205 In the
meantime, 23andMe is looking for new markets abroad, where
standards are less restrictive and the consumers will not be bound
by the FDA’s ruling.206 The FDA’s attempts to slow the growth of
the industry may prove fruitless due to other open-data source
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desktop applications 207 and the growth of other internationally
based genetic sequencing firms.208 While the FDA’s concerns are
not completely unfounded, regulators might not understand the
true nature of the risk involved in receiving genetic information
from these DTC genetic testing services.209
Between the FDA banning all health-related genetic tests by
23andMe and Interleukin’s unfettered offering of Inherent Health
lies a compromise. First, while the FDA should certainly play a
role in the regulation of these genetic tests, it should allow for an
acceleration of genetic test approval after 23andMe’s pending
initial approval of the Bloom syndrome test. Second, the FTC
should step in to help make sure that consumers are not misled into
purchasing products with unfounded health-related claims and are
able to read and understand the terms of service of these products.
Third, CMS under CLIA should ensure that Interleukin’s Inherent
Health tests are analytically valid, but that they also have clinical
validity and utility. Fourth, legislators should clarify what the role
of GINA should be for DTC genetic testing companies. While
there is still room for state regulation, in an increasingly
international platform for these tests, it might be prudent for the
federal government to take a larger role in the regulation of DTC
tests. Finally, while isolated naturally occurring DNA sequences
may no longer be patentable, there remain significant opportunities
for DTC genetic testing companies to patent their discoveries.
These different regulatory mechanisms need to coordinate together
to help this burgeoning industry grow in a responsible, sustainable
way.
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